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Plateau-phase cultures: an experimental model for
identifying drugs which are bioactivated within the
microenvironment of solid tumours
RM Phillips and MRK Clayton
Clinical Oncology Unit, University of Bradford, Bradford BD7 IDP, UK
Summary A commonly used technique for evaluating potential bioreductive drugs is the determination of hypoxic cytotoxicity ratios in vitro.
This experimental model, however, does not accurately mimic the tumour microenvironment, as other factors (such as reduced pH, poor
nutrient status, low cell proliferation rates and high catabolite concentrations) are not incorporated into the design of the assay. Plateau-phase
monolayer cultures possess many of these characteristics, and this study compared the response of plateau-phase and exponentially
growing human colon carcinoma cells (DLD-1) with a series of standard and bioreductive compounds. All drugs tested were added directly to
conditioned medium and three patterns of chemosensitivity were observed. In the case of doxorubicin, vinblastine and 5-fluorouracil,
exponentially growing cells were significantly more responsive than plateau-phase cultures. ThioTEPA and MeDZQ (2,5-diaziridinyl-1,4-
benzoquinone) were equally cytotoxic to both populations of cells. Tirapazamine (SR4233), RSU 1069, mitomycin C and EO-9, however,
were preferentially toxic towards plateau-phase compared with exponentially growing cells. While the exact mechanisms responsible for
these observations in each case are not known, this study suggests that plateau-phase cultures may prove to be a useful experimental model
in the evaluation of drugs designed to work preferentially within the tumour microenvironment.
Keywords: bioreductive drugs; bioactivation; plateau phase; microenvironment
A characteristic feature of many solid tumours is that their
vascular supply is inadequate leading to regions ofthe tumour that
are poorly perfused with blood (Thomlinson and Gray, 1955;
Denekamp, 1986). This property of solid tumours introduces
several factors that reduce the effectiveness ofboth chemotherapy
and radiotherapy. These include gradients of oxygen tension,
extracellular pH, nutrients, catabolites, altered expression of
biologically and pharmacologically important proteins and cell
proliferation rates, all ofwhich vary as a function ofdistance from
a supporting blood vessel (Denekamp, 1986; Sutherland, 1988;
Vaupel et al, 1989; Brown and Garccia, 1994). Tumour cells that
reside some distance away from a blood vessel therefore exist in
a microenvironment which is quite distinct from normal physio-
logical conditions, and there is considerable interest in trying to
exploit this physiological difference to obtain a selective therapy
for solid tumours (Kennedy, 1987; Tannock and Rotin, 1989;
Gerweck and Seetharaman, 1996).
A number ofstrategies have been employed to try and eradicate
these cells, particularly with the development of bioreductive
drugs which are prodrugs that are enzymatically reduced to cyto-
toxic species underhypoxic conditions (Brown and Garccia, 1994;
Workman, 1994). Several hypoxic cell cytotoxins have been
developed, such as tirapazamine and RSU 1069, which were iden-
tified largely on the basis ofdifferential response ofcells under air
and nitrogen (Zeman et al, 1986; Brown, 1993; Workman and
Stratford, 1993). The only variable assayed in these studies is the
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oxygenation status ofthe cultures at the time ofdrug exposure and,
in this respect, the model only partly mimics the conditions found
within the microenvironment of tumours (Stratford et al, 1990).
Drugs which are activated by conditions other than hypoxia (e.g.
by acidic pH) may be missed, and there is therefore considerable
merit in using experimental models that closely mimic the tumour
microenvironment in its entirety to identify compounds of this
class. Any compounds identified using such a model could be clas-
sified as 'bioactivated drugs' as opposed to bioreductive drugs as
several factors may contribute towards cytotoxicity, not just
hypoxia. Multicellular spheroids and post-confluent multicell
layers (Durand and Olive, 1992; Pizao et al, 1993) closely mimic
conditions found within solid tumours, although both techniques
are labour intensive and are not suitable as a front line screen for
bioactivated pro-drugs. There is therefore a need to develop new
experimental models of the tumour microenvironment that retain
the simplicity required for the in vitro evaluation oflarge numbers
ofpotential prodrugs.
In the early 1970s, considerable interest centred upon the use of
plateau-phase monolayer cultures as an in vitro model ofthe non-
cycling fraction of cells that exist within solid tumours, and
numerous studies have compared the response of plateau-phase
cells with cells in exponential growth to both radiotherapy and
chemotherapy (Hahn and Little, 1972; Twentyman and Bleehen,
1973; Barranco and Novak, 1974; Drewinko et al, 1981). Plateau-
phase cultures have been extensively characterized and, in addi-
tion to a reduction in cellular proliferation rates, a decrease in
extracellular pH, oxygen tension and nutrient status plus an
increase in lactic acid and catabolite concentrations have been
described (Hahn and Little, 1972; Glinos et al, 1973; Mauro et al,
1974; Bhuyan et al, 1977). These characteristics of plateau-phase
cultures, therefore, closely resemble those found within the
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Figure 1 Growth characteristics of DLD-1 cells (A), the change in extracellular pH (B) and mitotic indices (C) throughout the growth curve. Each point
represents the mean of three independent experiments ± standard deviations
hypoxic microenvironment of tumours, whereas cells in exponen-
tial growth exist in conditions that are analogous to cells growing
close to a blood vessel (i.e. good nutrient status, active cell pro-
liferation, low catabolite concentration, physiological pH, etc.).
These differences between plateau-phase and exponentially
growing cells provide a foundation for the development of a novel
screening strategy, the aim of which is to identify pro-drugs that
are bioactivated under conditions which mimic the microenviron-
ment of tumours. Compounds would be selected for further evalu-
ation if they are preferentially toxic towards plateau-phase cells
compared with exponentially growing cells. In order to validate
this proposed screening strategy, the principal aim of this study is
to determine whether or not the sensitivity of DLD- I human colon
carcinoma cells at different stages of the growth curve can distin-
guish between a series of standard anti-cancer agents and known
bioreductive drugs using the selection criteria outlined above.
MATERIALS AND METHODS
Culture conditions
DLD-1 human colon carcinoma cells (Dexter et al, 1979) were
routinely maintained as monolayer cultures in RPMI-1640
medium (Life Technologies, Paisley, UK) supplemented with 10%
fetal calf serum (Advanced Protein Products, Brierly Hill, UK),
sodium pyruvate (1 mm, Life Technologies), L-glutamine (1 mM,
Life Technologies) and penicillin/streptomycin (100 IU ml-1 and
100 ,ug ml-', Life Technologies).
Growth characteristics
DLD- 1 cells were seeded at an initial density of lx I05 cells per T-
25 flask containing 10 ml of growth medium and incubated at
37°C. Total cell number was determined daily by harvesting cells
by trypsinization and counting cells using a haemocytometer.
Extracellular pH was monitored daily using a pH electrode (Orion
Research). Mitotic indices were determined from cells grown on
cover slips (placed inside T-25 flasks) which were stained with
haematoxylin and eosin. A total of ten fields ofview per data point
were counted (x 25 objective), and approximately 200-300 cells
per data point were counted. All experiments were performed
in triplicate.
Chemosensitivity studies
Drugs used in this study include doxorubicin (Farmitalia Carbo,
Barnet, UK), vinblastine (Sigma, Poole, UK), 5-fluorouracil
(Sigma), ThioTEPA (a gift from Lederle Laboratories, Gosport,
UK), mitomycin C (Kyowa Hakko Kogyo, Tokyo, Japan), EO-9
(The New Drug Development Office ofthe European Organisation
for the Reseach and Treatment of Cancer), tirapazamine (a gift
from Sanofi Winthrop, USA), RSU 1069 and MeDZQ (2,5-
dimethyl-3,6-diaziridinyl-1,4-benzoquinone; a gift from Dr J
Butler, Paterson Institute, Manchester, UK). EO-9 and MeDZQ
were dissolved in dimethyl sulphoxide (DMSO), aliquoted and
stored at -80°C. All other compounds were dissolved in sterile
saline, aliquoted and stored at -80°C. DLD-1 cells were set up at
an initial density of 1 x I05 cells per T-25 flask containing 10 ml of
medium and exposed to drugs on days 2 (exponential phase) and
days 7 (plateau phase) of the growth curve. All drugs were added
directly to the conditioned medium (< 100 gl aliquots) for 1 h
(with the exception of vinblastine and tirapazamine, for which
drug exposure times of 3 h were used, and 5-fluorouracil, for
which 6 h drug exposure times were used). Extended drug expo-
sure times were required to generate full dose-response curves
without depleting drug stocks. Following drug exposure, mono-
layers were washed twice with Hanks' balanced salt solution, and
cells were harvested by trypsinization. A total of I x 101 cells in
200 1 offresh RPMI-1640 medium (not conditioned) were plated
into each well of a 96-well plate, and cells were incubated at 37°C
for 5 days in an humidified atmosphere containing 5% carbon
dioxide. It should be stressed that cells treated on both days 2 and
7 of the growth curve were subjected to identical post-drug expo-
sure recovery periods of 5 days. Following incubation, 20 gl of
MTT (5 mg ml-') was added to each well and incubated for a
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Figure 2 The response of DLD-1 cells to doxorubicin (A) and EO-9 (B) on days 2-8 (inclusive) of the growth curve. Each point represents the mean of three
independent experiments + standard deviations
further 4 h. Medium plus MTT was removed from each well, and
the formazan crystals were dissolved in 150 gl of DMSO. The
absorbance of the resulting solution measured at 550 nm in an
ELISA spectrophotometer. Results were expressed in terms of per
cent survival, taking the absorbance of control cultures to be 100
% survival. Chemosensitivity was expressed in terms of IC50
values (concentration required to kill 50% of the cell population),
and all assays were performed in triplicate.
RESULTS
Growth characteristics of DLD-1 cells
Growth curves for DLD-1 cells together with the change in extra-
cellular pH and mitotic indices are presented in Figure 1.
Following an initial lag phase of 24 h, DLD-1 cells entered expo-
nential growth (population doubling time of 21 h) and reached
plateau phase on day 6 (Figure 1A). Extracellular pH decreased
from 7.5 ± 0.2 on day 0 to 6.7 ± 0.15 on day 8 ofthe growth curve
(Figure IB). Mitotic indices reached a peak on day 3 (4.73+
0.38%) and progressively decreased to 0.49 ± 0.21% on day 8
(Figure IC).
Chemosensitivity studies
The response of DLD-1 cells exposed to doxorubicin and EO-9
at various stages of the growth curve are presented in Figure 2.
As cells progressed through the growth curve, resistance to
doxorubicin increased (Figure 2A), particularly between days
4 and 7 of the growth curve. In the case of EO-9, DLD-1 cells
progressively became more sensitive as cultures matured into
plateau phase (Figure 2B). A comparison between the response of
cells in early exponential growth (day 2) and plateau phase (day 7)
to a series ofcompounds is presented in Figure 3. Three patterns of
chemosensitivity were observed. In the case of doxorubicin,
vinblastine and 5-fluorouracil exponentially growing cells were
significantly more responsive than the same cells in plateau phase
(Figure 3A). ThioTEPA and MeDZQ were equally effective
against plateau-phase cells as exponentially growing cells (Figure
3B). Finally, EO-9, mitomycin C, tirapazamine and RSU 1069
were preferentially cytotoxic towards plateau-phase cultures com-
pared with exponentially growing cells (Figure 3C).
DISCUSSION
The principal objective of this study was to develop a novel cell-
based screening assay that could be used to identify drugs that are
activated under conditions which mimic the tumour microenviron-
ment. Plateau-phase cultures closely mimic the microenvironment
oftumours, in that cell proliferation rates are reduced, the extracel-
lular pH is acidic, nutrient levels are low, catabolite concentrations
are high and oxygen tension is low (Figure 1; Hahn and Little,
1972; Glinos et al, 1973). The assay described in this study is
therefore quite distinct from currently available assays used to
evaluate bioreductive drugs, in that it assesses a compound's
ability to be activated under conditions that mimic several proper-
ties ofthe tumour microenvironment, notjust hypoxia. The ability
to kill non-proliferating cells is essential ifthis class ofcompounds
is going to be effective in the treatment ofsolid tumours and this is
a key feature ofthe proposed screening programme.
The use of plateau-phase cultures has several additional advan-
tages over other models of the tumour microenvironment, such as
multicellular spheroids. Firstly, it is a technically simple model in
which drugs are added directly to the conditioned medium and
chemosensitivity assessed using conventional assays, such as
clonogenic or MTT assays. In the case of MTT assays, however,
problems can occur with drugs that are either mitochondrial
poisons or cause an increase in mitochondrial density or activity
(Pagliacci et al, 1993; Pritsos and Vimalachandra, 1995). Provided
that short drug exposures are followed by a long drug-free
recovery period (5 days in this study), then many of these prob-
lems can be eliminated. Secondly, it would detect drugs that are
activated by conditions other than hypoxia alone, such as low pH,
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Figure 3 Comparison between the response of exponentially growing (E, open bars) and plateau-phase (P, hatched bars) DLD-1 cells to doxorubicin,
vinblastine, 5-fluorouracil, MeDZQ, ThioTEPA, RSU 1069, tirapazamine, mitomycin C and EO-9. Each point represents the mean of three independent
experiments + standard deviations
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or by combinations of environmental factors, and it would assess
'bioactivation' as opposed to classical bioreduction by hypoxia.
Thirdly, cells are able to biochemically adapt to the stressful envi-
ronmental conditions typically found at plateau phase. This point
is particularly significant in view ofthe growing body ofevidence
suggesting that the expression of various proteins is influenced by
microenvironmental conditions (Brown and Garccia, 1994).
Proteins, such as oxygen-regulated proteins (ORP) and glucose-
regulated proteins (GRP), are induced under conditions of low
oxygen tension and, although their specific cellular functions are
not clear, they represent a series of potentially novel targets for
drug design (Sciandra et al, 1984; Heacock and Sutherland, 1990;
Brown and Garccia, 1994). As conditions of low oxygen tension
and poor nutrient status exist at plateau phase (Hahn and Little,
1972; Glinos et al, 1973), these cells may therefore be biochemi-
cally similar to cells inside the tumour microenvironment,
although further work is required to verify this hypothesis. Finally,
there are no drug delivery problems provided that the cultures do
not 'pile up' as they reach plateau phase. For any drug that is
designed to be bioactivated within the tumour microenvironment,
an essential characteristic of this compound is that it must be able
to penetrate several layers of cells to reach its target. In the early
stages of drug development, however, a drug's ability to penetrate
multicell layers is not critical, as the prime objective is to identify
compounds that have the potential to be bioactivated under appro-
priate conditions. Drug penetration barriers could be identified in
more stringent secondary screens (using spheroids for example),
and this problem could be addressed through either an analogue
development programme or the formulation of compounds into
appropriate drug delivery vehicles.
The results of this study demonstrate that the proposed
screening strategy can distinguish between standard anti-cancer
drugs and known bioreductive agents, based upon the response of
cells at different stages ofthe growth curve. In the case oftirapaza-
mine, E09, mitomycin C and RSU 1069, DLD-1 cells were more
sensitive to these compounds in the plateau phase of the growth
curve than the same cells in exponential growth (Figures 2 and
3C). Previous studies have reported that mitomycin C is as active
against plateau-phase cells as exponentially growing cells,
although this study replaced the conditioned medium with fresh
medium immediately before drug exposure (Drewinko et al, 1981).
An essential component of the assay described in this study is that
drugs are added directly to conditioned medium, in the belief that
drug exposures should be performed under conditions that mimic
the tumour microenvironment. Nevertheless, these results suggest
that if these compounds can be efficiently delivered to the tumour
microenvironment, then preferential cell kill will occur at this site
relative to cells under physiological conditions. This has been
demonstrated in SCCVII tumours treated with RSU1069 and tira-
pazamine for which greater DNA damage (and cell kill with RSU
1069) has been reported in the poorly perfused regions of SCCVII
tumours compared with well-perfused regions of this tumour
model (Olive, 1995 a,b). For vinblastine, doxorubicin and 5-fluo-
rouracil, plateau-phase cells were more resistant than cells in the
exponential phase (Figure 3A), whereas ThioTEPA and MeDZQ
were equally active against both exponential and plateau-phase
cells (Figure 3B). Several possible factors may contribute to the
observed patterns ofchemosensitivity, including enhanced potency
under hypoxic or acidic conditions (Kennedy et al, 1985; Stratford
et al, 1986; Phillips et al, 1992; Brown, 1993). In addition, the
expression and activity ofDT-diaphorase, which plays a key role in
the activation of quinone-based drugs (Walton et al, 1991; Ross et
al, 1994), increases under both hypoxia and as cells move into the
plateau phase ofthe growth curve (O'Dwyer et al, 1994; Phillips et
al, 1994; Plumb and Workman, 1994). The conditions that exist in
plateau-phase cells are therefore complex, and the final outcome of
chemotherapy is likely to be due to a complex interaction between
several factors (such as differential drug transport, altered drug
stability or activity, DNA repair status and cell kinetic factors, etc.)
as opposed to a change in one parameter only. This is particularly
relevant to both ThioTEPA and MeDZQ as increased activity
against plateau-phase cells might be expected as a result of the
increased potency of ThioTEPA in vitro under acidic conditions
and elevated levels of DT-diaphorase (which activates MeDZQ) at
plateau phase (Phillips et al, 1988; Ross et al, 1994). The fact that
ThioTEPA and MeDZQ are as active against plateau-phase cells as
exponentially growing cells illustrates the point that the final
outcome of chemotherapy is a fine balance between activation or
the induction of damage on the one hand and how cells deal with
potentially toxic lesions on the other. While unravelling the mech-
anisms responsible for these effects would provide vital informa-
tion about a compound's mechanism of action, it is beyond the
scope ofthis study.
In conclusion, plateau-phase monolayer cultures may represent
a simple model of the complex microenvironment of solid
tumours. The findings ofthis study suggest that the use ofplateau-
phase cultures to identify potential bioactivated pro-drugs is tech-
nically feasible and may be useful as a front-line screen for this
class ofcompounds. Further validation ofthis proposal is required
with particular emphasis being placed on expanding the number of
drugs evaluated and the number of cell lines used. It is envisaged
that the interesting compounds which emerge from this initial
screening programme would be evaluated in more stringent
secondary screening programmes incorporating experimental
models that closely mimic the three-dimensional properties of
solid tumours. Several experimental models are currently avail-
able, particularly multicellular spheroids and post-confluent multi-
cell layers (Sutherland, 1988; Pizao et al, 1993). Both these
models not only have well-characterized gradients of oxygen, cell
proliferation rates, pH, nutrient status, etc. but also incorporate the
important question of drug penetration and are therefore suitable
for use as a secondary screening process. In addition, bioactivated
drugs would have to be used in combination with standard thera-
pies that target the well-oxygenated fraction of tumour cells, and
the question of synergy between bioactivated compounds and
radiotherapy or conventional chemotherapeutic agents can be
addressed in these secondary screening models. As with any
screening strategy, the ultimate value of any experimental model
will depend upon whether activity in vitro translates into activity
in vivo (Phillips et al, 1990), and further studies to determine the
predictive value of this cellular-based screening assay are
currently in progress.
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